AGIOS PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-412.8M | $673.7M | $-352.1M | $-231.8M | $1.60B | $-327.4M | $-411.5M | $-346.0M |
| Depreciation & Amortization | — | — | — | — | — | — | $8.1M | $7.2M |
| Depreciation | $5.2M | $5.7M | $6.6M | $8.4M | $8.8M | $9.4M | $8.0M | $7.2M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $52.6M | $42.8M | $44.8M | $49.3M | $53.5M | $61.6M | $58.1M | $73.4M |
| Net Cash from Operating Activities | $-373.0M | $-389.8M | $-296.1M | $-309.5M | $-407.3M | $-290.8M | $-370.6M | $-304.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $4.3M | $1.7M | $999.0K | $4.9M | $5.7M | $14.1M | $12.0M | $7.0M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $377.2M | $363.4M | $239.6M | $243.3M | $1.25B | $75.7M | $91.4M | $-273.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $8.7M | $14.4M | $5.4M | $2.4M | $-765.8M | $261.5M | $289.6M | $546.0M |
| Net Change in Cash | $12.9M | $-12.0M | $-51.1M | $-63.9M | $75.7M | $46.5M | $10.4M | $-32.2M |
| Free Cash Flow | $-377.3M | $-391.5M | $-297.1M | $-314.4M | $-413.1M | $-304.9M | $-382.7M | $-311.4M |